PG
Insider
Pushkal Garg
EVP Chief R&DPushkal Garg (EVP Chief R&D) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $2.3M of ALNY (5,170 sh across 10 lots, as filed), executed Oct 2 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$6.4M
shares × price, as filed
Last traded
Mar 5
Filed Mar 6
Median ADV $470.9M across their filed names
Open performance→Volume by month
Buys $0
Sells $26.3M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ALNYRecent filings
ALNYSALE
Alnylam Pharmaceuticals, Inc.
View filing →
$1.1M3,521 sh across 6 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $821K
2,549 sh across 6 lots
Exec Mar 2
Filed Mar 4 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $1.4M
4,360 sh across 3 lots
Exec Feb 27
Filed Mar 2 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $695K
2,242 sh × $310.08
Exec Feb 13
Filed Feb 17 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $2.3M
5,170 sh across 10 lots
Exec Oct 2 2025
Filed Oct 3 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $1.2M
2,523 sh across 8 lots
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $2.9M
9,766 sh across 2 lots
Exec Mar 21 2025
Filed Mar 25 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $142K
583 sh × $243.13
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET More filings →